Yes. For travelers heading to regions with a high risk of bacterial diarrhea, a typical regimen is 200 mg taken three times daily for three days, beginning at the onset of symptoms. This approach helps shorten the duration of diarrhea and reduce dehydration risk.
Rifaximin is minimally absorbed from the gastrointestinal tract, allowing it to act locally on gut bacteria while limiting systemic side effects. This property distinguishes it from most systemic antibiotics, which circulate throughout the body.
It is approved for preventing recurrence of hepatic encephalopathy in adults with liver cirrhosis. However, dosing must be individualized, especially in severe liver impairment (Child-Pugh C), and therapy should be overseen by a hepatology specialist.
Clinical studies have shown that many patients notice a reduction in abdominal pain and stool frequency within the first week of a 14-day course of 550 mg three times daily. Full therapeutic benefit is usually assessed at the end of the two-week treatment period.
Current evidence does not indicate a significant interaction between rifaximin and oral contraceptives, as rifaximin’s poor systemic absorption limits enzyme-mediated effects. Nevertheless, patients should inform their healthcare provider of all medications they are taking.
Severe or persistent abdominal pain could signal a serious adverse event, such as Clostridioides difficile infection. Seek immediate medical attention to evaluate the cause and determine whether the medication should be discontinued.
No. Rifaximin targets bacterial pathogens and does not have activity against viruses that cause gastroenteritis. For viral infections, supportive care and hydration are the mainstays of treatment.
Xifaxan may be taken with or without food; food does not significantly alter its concentration in the gut lumen. Some patients prefer taking it with meals to reduce mild stomach upset.
Store the tablets in a dry, temperature-controlled environment, such as a travel pouch away from direct sunlight or heat sources. Avoid leaving them in a car trunk or in extreme temperatures, which could degrade the medication.
Xifaxan is the branded formulation, often priced higher than generic rifaximin tablets available after patent expiry. Pricing varies across pharmacies and regions within the UK, and patients may discuss cost-saving options with their prescriber or pharmacist.
Xifaxan is a brand-name medication that contains the antibiotic rifaximin as its active ingredient. It belongs to the rifamycin class of antibiotics and is supplied as a oral pill in strengths of 200 mg, 400 mg, and 550 mg. In the United Kingdom, Xifaxan is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available only with a prescription.
Rifaximin exerts its antibacterial effect by binding to the β-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting RNA synthesis and bacterial protein production. Because the molecule is poorly absorbed from the gastrointestinal tract, it remains largely within the lumen of the gut, targeting pathogenic bacteria while leaving systemic exposure minimal. This localised action explains its rapid onset, with clinical improvement often observed within a few days of therapy, and its limited systemic side-effect profile.
These indications are based on approvals from the MHRA and the European Medicines Agency (EMA).
Some clinical studies have investigated rifaximin for SIBO, showing symptom improvement in many participants. Because SIBO is not an approved indication for Xifaxan in the UK, its use for this condition is considered off-label.
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment.
These reactions are usually mild and transient, resolving without the need for medical intervention.
If any of these occur, seek medical attention promptly.
All tablets should be swallowed whole with a glass of water. Do not crush, chew, or split the tablets, as this could affect the intended release profile.
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for the missed one.
Symptoms may include nausea, vomiting, abdominal pain, and diarrhea. In severe cases, seek emergency medical care. There is no specific antidote; treatment is supportive.
Xifaxan does not typically require tapering. Therapy can be stopped abruptly under medical guidance, though abrupt cessation may lead to recurrence of the underlying condition (e.g., hepatic encephalopathy).
Patients should maintain regular follow-up appointments to evaluate treatment effectiveness and any emerging side effects.
This article provides educational information about Xifaxan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
